SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
--------------
Date of Report (Date of earliest event reported): November 14, 2002
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 000-19319 04-3039129
(state or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification No.)
130 WAVERLY STREET
CAMBRIDGE, MA 02139-4242
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 444-6100
-------------------------------------------------------------------
ITEM 9. REGULATION FD DISCLOSURE.
The Quarterly Report on Form 10-Q for the period ending September 30,
2002 by Vertex Pharmaceuticals Incorporated was accompanied by certifications by
the company's principal executive officer, Joshua S. Boger, and principal
financial officer, Ian F. Smith, pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.
A copy of the certifications is attached hereto as Exhibit 99.1.
EXHIBIT INDEX
Exhibit 99.1 Certification pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date: November 14, 2002 /s/ IAN F. SMITH
--------------------------------------
Ian F. Smith
Vice President and Chief Financial
Officer